Figure 6. FR104 treatment does not impede adoptive Treg cellular therapy.

(A) Mice received an adoptive transfer of 10 × 10⁶ PBMCs together with a therapeutic dose of 5 × 10⁶ ex vivo–expanded Tregs and were then treated with saline (n = 5), FR104 (n = 5), or CTLA4-Ig (n = 5). (B) CTLA4-Ig together with Treg treatment did not promote an extension in graft survival compared with CTLA4-Ig alone (P = 0.2338). By contrast, FR104 had synergistic effects with Treg cellular therapy, promoting an extension of survival beyond that of Tregs or FR104 alone (FR104 vs. FR104+Treg, P = 0.0269; Treg vs. FR104+Treg, P = 0.3077, log-rank test). (C) Chimerism levels of human CD45⁺ cells in the peripheral blood on day 21 and day 28 after adoptive transfer.